

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
6750-173-999
(305158-999171)APPLICATION NO
10/607,563

APPLICANT

Donald J. KYLE et al.

FILING DATE

June 27, 2003

GROUP

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,439,606	03/27/1984	Du et al.	544	356	
	A02	4,450,272	05/22/1984	Du et al.	544	357	
	A03	5,039,680	08/13/1991	Imperato et al.	514	304	
	A04	5,075,341	12/24/1991	Mendelson et al.	514	282	
	A05	5,198,459	03/30/1993	Imperato et al.	514	397	
	A06	5,232,934	08/03/1993	Downs	514	345	
	A07	5,430,033	07/04/1995	Cliffe et al.	514	254	
	A08	5,442,064	08/15/1995	Pieper et al.	544	360	
	A09	5,461,047	10/24/1995	Hansen Jr. et al.	514	211	
	A10	5,556,837	09/17/1996	Nestler et al.	514	21	
	A11	5,556,838	09/17/1996	Mayer et al.	514	25	
	A12	5,574,052	11/12/1996	Rose et al.	514	343	
	A13	5,756,504	05/26/1998	Bock et al.	514	252	
	A14	5,762,925	06/09/1998	Sagen	424	93.7	
	A15	5,789,412	08/04/1998	Halazy et al.	514	255	
	A16	5,792,768	08/11/998	Kulagowski et al.	514	252	
	A17	5,792,769	08/11/1998	Lu et al.	514	255	
	A18	6,028,195	02/22/2000	Cho et al.	544	360	
	A19	6,109,269	08/29/2000	Rise et al.	128	898	
	A20	6,204,284	03/20/2001	Beer et al.	514	412	
	A21	6,329,395	12/11/2001	Dugar et al.	514	329	
	A22	6,423,716	07/23/2002	Matsuno et al.	514	252.02	
	A23	US 2002/019389	02/14/2002	Kim et al.	514	213.01	
	A24	US 2003/0153596	08/14/2003	Suh et al.	514	311	
	A25	US 2003/0158188	08/21/2003	Lee et al.	514	228.2	
	A26	US 2003/0158198	08/21/2003	Lee et al.	514	241	
	A27	US 2003/0212140	11/13/2003	Suh et al.	514	575	
	A28						



FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	B01	WO 96/21648	07/18/1996	PCT			
	B02	WO 98/00402	01/08/1998	PCT			
	B03	WO 99/07672	01/18/1999	PCT			
	B04	WO 00/52001	09/08/2000	PCT			

B05	WO 02/05819	01/24/2002	PCT				
B06	WO 03/022809 A2	03/20/2003	PCT				
B07	WO 03/062209 A2	07/31/2003	PCT				
B08	WO 03/068749 A1	08/21/2003	PCT				
B09	NL 7 804 136 A	04/27/1979	Netherlands (w/ English Abstract)			XXX	
B10	EP 1 122 242 A1	08/08/2001	EPC				
B11	Int. Search Report of WO 2004/002983 A3	01/23/2004	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Berkow et al., "The Merck Manual of Medical Information," pp. 345-350, 1997
C02	Berkow et al., "The Merck Manual of Medical Information," pp. 352-355, 1997
C03	Berkow et al., "The Merck Manual of Medical Information," pp. 496-500, 1997
C04	Berkow et al., "The Merck Manual of Medical Information," pp. 525-526, 1997
C05	Berkow et al., "The Merck Manual of Medical Information," pp. 528-530, 1997
C06	Berkow et al., "The Merck Manual of Medical Information," pp. 530-532, 1997
C07	Berkow et al., "The Merck Manual of Medical Information," pp. 631-634, 1997
C08	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Rice," Nature Neurosci., 4(9):873-874, 2001
C09	Cooke, "Glycopyrrolate in Bladder Dysfunction," SA Medical J., 63:3, 1983
C10	Di Marzo et al., "Endovanilloid Signaling in Pain," Current Opinion in Neurobiology, 12:372-379, 2002
C11	Dogrul et al., "Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, A Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, in Experimental Neuropathic Pain in Rats," Neurosci. Lett., 292(2):115-118, 2000
C12	Foley, "Pain" Cecil Textbook of Medicine, pp. 100-107, 1996
C13	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," Pharmacol., Biochem. & Behavior, 73:401-410, 2002
C14	Fundytus et al., "In vivo Antinociceptive Activity of Anti-Rat mGluR ₁ and mGluR ₅ Antibodies in Rats," NeuroReport, 9:731-735, 1998
C15	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy after Nerve Injury in Rats," British J. Pharmacol., 132:354-367, 2001
C16	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," CNS Drugs, 15:29-58, 2001
C17	Goodman and Gillman's the Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird Eds., 9 th ed. 1996)
C18	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," Annu. Rev. Gerontol. Geriatr., 9:74-119, 1989
C19	Kwak et al., "A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance," Neurosci., 84:619-626, 1998
C20	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," J. Urology, 128:396-398, 1982
C21	Matsuno et al., "Potent and Selective Inhibitors of PGDF Receptor Phosphorylation," J. Medicinal Chem., 45:4513-23, 2002
C22	Meyer et al., "5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as Antihypertensive Agents, J. Medicinal Chem., 32:593-7, 1989
C23	Mirakhur et al., "Glycopyrrolate: Pharmacology and Clinical Use," Anaesthesia, 38:1195-1204, 1983
C24	Ohkubo et al., "The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol," J. Dent. Res., 76(4): April 1997
C25	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-Like Effects in Rats," Neuropharmacol., 41:413-420, 2001
C26	Pan et al., "Soluble Polymer-Supported Synthesis of Arylpiperazines," Tett. Lett., 39:9505-9508 1998
C27	Reid et al., "Synthese and Reaktionem Neuer Thiazol-Und Triazol-Abkömmlinge," Chemische Berichte, 116:(4) 1548, 1983
C28	Resnick, "Urinary Incontinence," Lancet, 346:94-99, 1995
C29	Tatarczynska et al., "Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, A Potent, Selective and Systemically Active mGluR5 Receptor Antagonist," British J. Pharmacol., 132(7):1423-1430, 2001

	C30	Urban et al., "In Vivo Pharmacology of SDZ 249-665, A Novel, Non-Pungent Capsaicin Analogue," Pain, 89:65-74 2000
	C31	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain," Neuropharmacol., 40:1-9, 2000
	C32	Wein, "Pharmacology of Incontinence," Urologic Clinics of North America, 22(3):557-577, 1995
	C33	Spooren et al., "Novel Allosteric Antagonists Shed Light on mGlu ₅ Receptors and CNS Disorders," Trends Pharmacol. Sci., 22(7):331-337, 2001
	C34	Wu et al., "Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach To Capsaicin Antagonist," Gen. Pharmac., 27(1):151-158 1996
	C35	

EXAMINER 	DATE CONSIDERED 10/12/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 6750-173-999 (CAM No. 305158-999171)	APPLICATION NO. 10/607,563
	APPLICANT: Donald J. KYLE et al.	
	FILING DATE: June 27, 2003	ART UNIT: 1623 CONF. NO.: 5149

U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	6,020,349	02/01/2000	Ankersen et al.	
	A29	6,083,960	07/04/2000	Ankersen et al.	
	A30	2004/0019099 A1	01/29/2004	Aslanian et al.	
	A31	2004/0048843 A1	03/11/2004	Ting et al.	
	A32	2004/0097483 A1	05/20/2004	Zeng et al.	
	A33	2004/0204397 A1	10/14/2004	Chaturvedula et al.	
	A34	2006/0004053 A1	01/05/2006	Arnould	
	A35				

FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
						YES NO
	B12	WO 02/18335 A1	03/07/2002	Yamanouchi Pharmaceutical Co., Ltd. and Toray Industries Inc.		XXX
	B13	WO 2004/064721 A2	08/05/2004	Tanabe Seiyaku Co., Ltd.		
	B14					

NON PATENT LITERATURE DOCUMENTS		
EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.
	C35	WRIGGLESWORTH et al., "Capsaicin-like Agonists," <i>Drugs of the Future</i> 23(5):531-538 (1998) ✓
	C36	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacol. Revs.</i> 51(2):159-211 (1999) ✓
	C37	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," <i>Molec. Pharmacol.</i> 56:581-587 (1999) ✓
	C38	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nociception," <i>Current Opinions in CPNS Investigational Drugs</i> 2(2):178-185 (2000) ✓
	C39	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," <i>Mol. Pharmacol.</i> 62(4):947-956 (2002) ✓
	C40	LOPEZ-RODRIGUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," <i>Mini-Revs in Medicinal Chem.</i> 3(7):729-748 (2003) ✓
	C41	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," <i>J. Pharmacol. Exper. Therapeutics</i> 306(1):387-393 (2003) ✓
	C42	

EXAMINER	DATE CONSIDERED 10/12/06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	